Takeda wants to join the likes of India's Hilleman Labs and Serum Institute and grab a piece of the low-cost vaccine pie. The Japanese pharma closed a €3 million ($3.3 million) equity investment in Belgium-based Univercell to use the latter's technology with vaccines in Takeda's pipeline to produce affordable vaccines for developing countries.
In South Africa, 40% of the national budget for vaccines is used to import Pfizer's Prevenar 13, according to Science and Technology Minister Naledi Pandor. To ease this burden, Pfizer and South Africa's Biovac Institute are entering a 5-year partnership to produce the vaccine domestically, Reuters reported.
Doctors Without Borders (MSF) often has a bone to pick with Big Pharma, especially when it comes to the industry's patents on expensive life-extending meds. As part of its latest tirade, the group is urging the South African government to override a patent for AbbVie's HIV drug, Aluvia, after shortages of the med cropped up in the country.
AstraZeneca has laid out a host of new manufacturing projects in recent months, including new biologics plants in Europe and the U.S. But while those projects are in the works, it has a new tablet plant in Russia that has just gone online.
If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of a large, well-funded company trying to create hybrid pharma and food products company that would treat conditions from stomach disorders to Alzheimer's disease.
Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.
Abbott Laboratories wlll expand its manufacturing, as well as other operations, in India, though a dollar amount was not given by the pharmaceutical giant.
Lately, Latin America has been leading the growth ranks for Merck KGaA's consumer health unit. And that's not set to change anytime soon, its leader says.
The Indian Drug Manufacturers' Association says the country's pharmaceutical contract manufacturing industry is growing at 20%.
Novartis has stood by its commitment to emerging markets even in rocky times. And now, it's furthering that commitment with an access initiative for low-income countries.